Seer, Inc. Stock Price, News & Analysis

Seer (Nasdaq: SEER) will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a live webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET. Live audio will stream on the Investor section of the company website at investor.seer.bio, and an archived replay will be posted on the website after the event.

Seer (Nasdaq: SEER) will present at the American Society of Human Genetics (ASHG) Annual Meeting, October 14-18, 2025 in Boston, highlighting how proteomics complements genomics to advance precision medicine.

Seer will host a featured CoLab session on October 16, 2025, 2:30-3:00 p.m. ET showcasing Proteograph-enabled multi-omic studies, including xenotransplantation immune profiling and isoform-specific biomarkers in idiopathic pulmonary fibrosis. Multiple independent research groups will also present Proteograph-generated findings on October 16 across poster and session formats, illustrating adoption of Seer’s Proteograph Product Suite for proteogenomic discovery and biomarker identification.

Seer (Nasdaq: SEER), a pioneer in proteomic insights, has appointed Isaac Ro to its Board of Directors. Ro brings significant financial leadership experience and deep sector expertise in life science tools and diagnostics. Currently a Partner at Catalio Capital Management, Ro has an impressive track record including serving as Executive Chairman of Haystack Oncology (acquired by Quest Diagnostics), CFO of Sema4 during its public listing, and CFO of Thrive Earlier Detection (acquired by Exact Sciences).

Prior to these roles, Ro led U.S. Medical Technology and Life Science Tools equity research teams at Goldman Sachs from 2010 to 2019. He currently serves on the boards of PinkDx and PrognomiQ, bringing valuable experience to support Seer's growth and platform development initiatives.

Seer (Nasdaq: SEER), a company focused on proteomic insights, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's management will engage in a fireside chat on September 9th at 12:20 PM ET.

Investors can access the presentation through a live webcast on the Investor section of Seer's website at investor.seer.bio. An archived version of the presentation will be made available after the conference.

Seer (Nasdaq: SEER), a life sciences company focused on proteomics, reported its Q2 2025 financial results with revenue of $4.1 million, representing a 32% year-over-year growth. The quarter was marked by the launch of their new high-throughput Proteograph ONE assay and SP200 automation instrument.

Key financial metrics include gross profit of $2.1 million with a 52% gross margin. Operating expenses decreased 21% to $22.6 million, while net loss improved to $19.4 million. The company maintains a strong balance sheet with $263.3 million in cash and investments. Seer reiterated its full-year 2025 revenue guidance of $17-18 million, projecting 24% growth at the midpoint.

Notable developments include a collaboration with Korea University for a 20,000-sample population-scale proteomics study focused on cancer diagnostics in young adults.

Seer (Nasdaq: SEER), a company focused on proteomic insights, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference in Boston. The company's management will engage in a fireside chat on August 13th at 9:00 a.m. ET.

Investors can access the presentation through a live webcast on the Investor section of Seer's website at investor.seer.bio, with an archived replay available after the event.

Seer (Nasdaq: SEER), a company specializing in proteomic insights, has scheduled its Q2 2025 financial results announcement for August 6, 2025. The company will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET on the same day.

Investors can access the live webcast through the Investor section at investor.seer.bio, where an archived replay will also be available after the event.

Seer (NASDAQ: SEER) and Korea University announced a groundbreaking 20,000-sample proteomics study to develop AI-driven cancer diagnostics for young adults. The three-year study, funded by Korea's K-Health MIRAE initiative, will analyze 15,000 cancer patients and 5,000 healthy controls using Seer's new Proteograph ONE Assay and SP200 Automation Instrument. The platform can process over 1,000 samples weekly, requiring only one mass spectrometry injection per sample and completing 80-sample batches in under 5 hours. The study leverages Seer's technology alongside Thermo Scientific's Orbitrap Astral mass spectrometer to identify up to 10 times more proteins than conventional methods. Samples will be sourced from leading Korean institutions including Seoul National University Hospital, National Cancer Center, and Samsung Medical Center. This collaboration aims to revolutionize early cancer detection and treatment in young adults through AI-powered diagnostics.

Seer (NASDAQ: SEER) has unveiled its new Proteograph® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument at ASMS 2025. The enhanced platform achieves groundbreaking improvements in proteomic analysis capabilities, processing over 1,000 samples per week per instrument - double the previous throughput. The new workflow reduces per-sample analysis costs by 60% compared to its 2021 release while identifying up to 10 times more proteins than traditional mass spec workflows.

Key advancements include automated run times under 5 hours for 80-sample batches, reduced operator-induced variability, and enhanced reproducibility. The system enables large-scale biomarker discovery, longitudinal disease studies, and comprehensive multi-center research. The new Proteograph Product Suite will be commercially available from June 1, 2025, through direct purchases and Seer's Technology Access Center.